The failure of semaglutide to slow Alzheimer's progression in a major phase 3 trial represents a significant setback for the emerging field of metabolic approaches to neurodegeneration, while highlighting the complexity of translating promising preclinical findings into human therapeutic success. The EVOKE(+) trials tested whether the widely-used diabetes and weight-loss medication could leverage its neuroprotective mechanisms to benefit Alzheimer's patients. Semaglutide, a GLP-1 receptor agonist, demonstrated no measurable impact on clinical progression markers compared to placebo across the study cohort. The drug's established effects on insulin sensitivity, inflammation reduction, and potential brain-derived neurotrophic factor enhancement had generated considerable optimism based on earlier observational studies and animal models. This null result joins a growing list of metabolic interventions that have struggled to translate laboratory promise into meaningful cognitive protection. The pharmaceutical approach to Alzheimer's continues facing fundamental challenges, with recent approvals of amyloid-targeting drugs showing modest benefits at best. The metabolic theory of neurodegeneration—suggesting that brain insulin resistance and glucose metabolism dysfunction drive cognitive decline—remains scientifically compelling despite this clinical disappointment. The EVOKE(+) findings may reflect issues with trial design, patient selection, dosing protocols, or intervention timing rather than invalidating the underlying metabolic hypothesis. For health-conscious adults, this reinforces that lifestyle interventions targeting metabolic health through diet, exercise, and weight management remain the most evidence-based approaches for cognitive preservation, while we await more sophisticated pharmaceutical solutions.